Chemotherapy parity laws: A remedy for high drug costs?

JAMA Internal Medicine

Volumn 174, Issue 11, 2014, Pages 1721-1722

  Wang, Bo ^a   Joffe, Steven ^b   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; HEALTH CARE DISPARITY; HEALTH PROGRAM; HUMAN; OUTPATIENT DEPARTMENT; PATIENT ADVOCACY; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; REIMBURSEMENT; SHORT SURVEY; UNITED STATES; COST; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COST ALLOCATION; COST SHARING; DRUG COSTS; HUMANS;

EID: 84925282720     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.4878     Document Type: Short Survey

References (8)

1. Experts in Chronic Myeloid Leukemia. The price of drugs for chronicmyeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.
2. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143-1152.
3. Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3)(suppl):46s-51s.
4. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
5. Johnson K, Blansett L, Mawrie R, et al. Innovation in cancer care and implications for health systems: global oncology trend report. IMS Institute for Healthcare Informatics. May 2014. http://340breform.org/userfiles/IMSH-Oncology-Trend-Report.pdf. Accessed August 11, 2014.
6. Howard DH. Drug companies' patient-assistance programs: helping patients or profits? N Engl J Med. 2014;371(2):97-99.
7. Pollack A. Health insurers pressing down on drug prices. New York Times, June 20, 2014. http://www.nytimes.com/2014/06/21/business/health-plans-bring-pressure-to-bear-20son-drug-prices.html. Accessed July 29, 2014.
8. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times, October 14, 2012. http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html?-r=0. Accessed August 8, 2014.